標(biāo)題: Titlebook: Hepatitis C Virus II; Infection and Diseas Tatsuo Miyamura,Stanley M. Lemon,Takaji Wakita Book 2016 Springer Japan 2016 Chronic Hepatitis.H [打印本頁(yè)] 作者: Hazardous 時(shí)間: 2025-3-21 18:44
書(shū)目名稱Hepatitis C Virus II影響因子(影響力)
書(shū)目名稱Hepatitis C Virus II影響因子(影響力)學(xué)科排名
書(shū)目名稱Hepatitis C Virus II網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Hepatitis C Virus II網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Hepatitis C Virus II被引頻次
書(shū)目名稱Hepatitis C Virus II被引頻次學(xué)科排名
書(shū)目名稱Hepatitis C Virus II年度引用
書(shū)目名稱Hepatitis C Virus II年度引用學(xué)科排名
書(shū)目名稱Hepatitis C Virus II讀者反饋
書(shū)目名稱Hepatitis C Virus II讀者反饋學(xué)科排名
作者: Kidnap 時(shí)間: 2025-3-21 20:59 作者: anagen 時(shí)間: 2025-3-22 03:04 作者: outer-ear 時(shí)間: 2025-3-22 05:08
akroskopischen und mikroskopischen Anatomie in Tabellenform. Dabei ist in nahezu allen Tabellen eine Spalte den funktionellen und klinischen Aspekten vorbehalten. übersichtlich und klar strukturiert, k?nnen die Inhalte leicht erlernt und - bei Bedarf - auch leicht wieder reproduziert werden.作者: 創(chuàng)新 時(shí)間: 2025-3-22 09:06 作者: laparoscopy 時(shí)間: 2025-3-22 15:53 作者: 異端邪說(shuō)2 時(shí)間: 2025-3-22 17:23 作者: Juvenile 時(shí)間: 2025-3-23 00:14 作者: Mutter 時(shí)間: 2025-3-23 04:07
Nicolas Tremblay,Alex Young Park,Daniel Lamarre Ph.D. Entscheidungen in komplexen Entscheidungssituationen überhaupt zustande kommen. Im übrigen kommen namhafte Protagonisten der Thematik zu dem Schluss, dass herk?mmliche Methoden ihre Probleml?sungskraft verloren haben.作者: CRANK 時(shí)間: 2025-3-23 07:04 作者: 核心 時(shí)間: 2025-3-23 11:26
r besch?ftigt haben, die glatte Muskulatur entweder gar nicht oder nur am Rande erw?hnen, mit der einzigen Ausnahme von H., dessen Beschreibung (1873) die einzige zutreffende ist, wie ich an Hand zahlreicher Pr?parate feststellen konnte.作者: 開(kāi)始發(fā)作 時(shí)間: 2025-3-23 16:16 作者: BLOT 時(shí)間: 2025-3-23 21:52 作者: Osteoporosis 時(shí)間: 2025-3-24 01:24 作者: Mingle 時(shí)間: 2025-3-24 02:56 作者: Adenoma 時(shí)間: 2025-3-24 09:08 作者: 流利圓滑 時(shí)間: 2025-3-24 10:58 作者: 哀求 時(shí)間: 2025-3-24 15:12
Terence N. Bukong,Banishree Saha,Gyongyi Szabo M.D., Ph.D. Aspekten vorbehalten. übersichtlich und klar strukturiert, k?nnen die Inhalte leicht erlernt und - bei Bedarf - auch leicht wieder reproduziert werden.978-3-540-58040-9978-3-642-95726-0Series ISSN 0937-7433 Series E-ISSN 2512-5214 作者: incarcerate 時(shí)間: 2025-3-24 21:38 作者: Merited 時(shí)間: 2025-3-25 02:49
Aspekten vorbehalten. übersichtlich und klar strukturiert, k?nnen die Inhalte leicht erlernt und - bei Bedarf - auch leicht wieder reproduziert werden.978-3-540-58040-9978-3-642-95726-0Series ISSN 0937-7433 Series E-ISSN 2512-5214 作者: 百科全書(shū) 時(shí)間: 2025-3-25 06:06
Natural History of Chronic Hepatitis Cse and hepatocellular carcinoma. Modeling data predicts that the number of individuals with cirrhosis is expected to double by 2030. Many of these individuals will be at risk for end-stage liver disease and hepatocellular carcinoma. Could substantially reduce risk of cirrhosis, decompensation, cancer, and liver-related deaths.作者: tariff 時(shí)間: 2025-3-25 07:44 作者: 喃喃而言 時(shí)間: 2025-3-25 14:28
http://image.papertrans.cn/h/image/425710.jpg作者: irreducible 時(shí)間: 2025-3-25 19:06 作者: 卷發(fā) 時(shí)間: 2025-3-25 21:16
Andrea L. Cox M.D., Ph.D.e Darstellung von Veit in der 2. Auflage dieses Handbuches Bd. 3, 2. H?lfte und die Bearbeitungen der jüngsten Zeit von Prankl im Payr-Zweifel (Handbuch der b?sartigen Geschwülste 1927, Bd. 3), von Bobert Meyer: Zeitschr. f. Geburtsh. u. Gyn?kol. Bd. 92, H. 2 und vor allem von Hitschmann in Halban-Seitz Bd. 7 und Sunde in der Acta gyn. scand..作者: 收藏品 時(shí)間: 2025-3-26 01:25
Tatsuo Miyamura M.D., Ph.D.vom Spatium pararectale trennt und die Eingeweide gewisserma?en an der seitlichen Beckenwand fixiert. Denn die Gef??e der Beckeneingeweide entspringen von den Vasa hypogastrica, die selbst durch ihre aus dem Becken durch das Foramen ischiadicum austretenden ?ste (Vasa pudendalia und glutea sup. et inf.) festgehalten sind.作者: 態(tài)學(xué) 時(shí)間: 2025-3-26 08:08
al nature of HCV infection. Based on recent data concerning the genetic- and geographical diversity of HCV, and increased global disease burden of HCV infection, challenges for global control of HCV infections 978-4-431-56776-9978-4-431-56101-9作者: 鎮(zhèn)壓 時(shí)間: 2025-3-26 08:33 作者: 單調(diào)女 時(shí)間: 2025-3-26 12:47
Piero Colombatto M.D.,Ferruccio Bonino M.D.,Luigi Civitano Ph.D.,Filippo Oliveri M.D.,Gabriele Ricco die der Bearbeitung eines so kleinen Tieres, sowohl durch die mühevolle Materialbeschaffung, als auch in technischer Hinsicht, im Wege stehen. M?ge angesichts dieser Schwierigkeiten entschuldigt werden, da? ich so manche Frage ganz oder zum Teil offen lassen mu?te.作者: 壓艙物 時(shí)間: 2025-3-26 19:24
Hepatic Fibrosis in Hepatitis C when comparing patients with cirrhosis relative to those with bridging fibrosis (Lok et al. 2009). With an estimated 180 million people infected by HCV worldwide, fibrosis and its progression to cirrhosis represent a major global problem (Rosen HR 2011).作者: 旁觀者 時(shí)間: 2025-3-27 00:00 作者: restrain 時(shí)間: 2025-3-27 01:21
HCV, Alcohol, and the Livern understanding of the various molecular cellular mechanisms by which HCV synergizes with alcohol to advance liver disease. Given the limited treatments available for HCV-infected patients who use alcohol, we also highlight new therapeutic targets and areas where more research would enhance our unde作者: nominal 時(shí)間: 2025-3-27 05:59 作者: 荒唐 時(shí)間: 2025-3-27 10:06 作者: instate 時(shí)間: 2025-3-27 15:38 作者: sterilization 時(shí)間: 2025-3-27 19:58
HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapiesoof-of-concept in humans for a novel class of selective anti-HCV agents specifically designed to inhibit an essential viral enzyme. The inclusion of protease inhibitors with the standard of care therapy established the first major therapeutic advancement against HCV infection. In conjunction with ot作者: semiskilled 時(shí)間: 2025-3-28 02:00
Mechanism of Action of Direct-Acting Antivirals: New Insights into the HCV Life Cyclecomplex, viral RNA synthesis, and virion assembly. DAAs currently used in the clinic include inhibitors that target the NS3/4A protease, the NS5A protein, and the NS5B RNA-dependent RNA polymerase. This review will discuss the mode of action of each of the major classes of antiviral drugs and how th作者: 鋼筆尖 時(shí)間: 2025-3-28 04:21
Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapye residual number of infected cells at the end of therapy and its outcome, regardless to HCV genotype, IL28B polymorphism and characteristics of the liver disease. This modeling approach was successfully applied in a pilot study to tailor the duration of peg-interferon and ribavirin therapy, as well作者: 秘方藥 時(shí)間: 2025-3-28 08:22 作者: 陳舊 時(shí)間: 2025-3-28 11:26
Global Control of Hepatitis C Virus Infection. Notably, risk factors and epidemiological parameters are very dynamic. To control HCV infection globally, we must establish a robust international network capable of monitoring the real time epidemiology of HCV and accounting for its increasing disease burden.作者: JECT 時(shí)間: 2025-3-28 17:45
Book 2016The authors represent a worldwide distribution of leaders in the field reflecting the global nature of HCV infection. Based on recent data concerning the genetic- and geographical diversity of HCV, and increased global disease burden of HCV infection, challenges for global control of HCV infections 作者: 單獨(dú) 時(shí)間: 2025-3-28 18:56
Natural History of Chronic Hepatitis Cs who are exposed to hepatitis C virus. Chronic infection with hepatitis C virus is a major cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma. The prognosis of chronic hepatitis C is highly variable and many host, viral and environment factors influence outcome. Approximately 作者: 最高點(diǎn) 時(shí)間: 2025-3-28 23:29 作者: Myelin 時(shí)間: 2025-3-29 03:45
Hepatic Fibrosis in Hepatitis Cncluding hepatocellular carcinoma (HCC), end-stage liver disease, the necessity for liver transplantation, or death. In fact, HCV is the leading cause of liver transplantation, accounting for more than 40?% of liver transplants in the United States (Organ Procurement and Transplantation Network 2010作者: 罵人有污點(diǎn) 時(shí)間: 2025-3-29 08:30
Hepatocellular Carcinoma and Hepatitis C Virusatitis C virus (HCV) infection is one major cause. In chronically infected hepatocytes, HCV directly induces oxidative stress, impairs DNA damage response, manipulates cell cycle control and generates insulin resistance, possibly promoting DNA mutations accumulated in host genome from hepatitis stag作者: DUST 時(shí)間: 2025-3-29 12:07
HCV, Alcohol, and the Livert is estimated that about 140 million and 170 million individuals worldwide suffer from alcohol dependence or chronic HCV infection respectively. ALD and HCV infection, independently, if not treated properly can progress to advanced liver disease including fibrosis, cirrhosis and ultimately hepatoce作者: ascetic 時(shí)間: 2025-3-29 16:53 作者: albuminuria 時(shí)間: 2025-3-29 22:15
Hepatitis C Virus Infection in Pregnancy and Childhoode a rise in plasma viral levels and decline in hepatic transaminases in the latter half of pregnancy, likely due in part to suppression of HCV-specific cellular immunity by maternofetal tolerance mechanisms. These changes reverse following delivery, with viremia sometimes declining sharply due to an作者: 預(yù)防注射 時(shí)間: 2025-3-30 02:21 作者: 變形 時(shí)間: 2025-3-30 07:24 作者: 半導(dǎo)體 時(shí)間: 2025-3-30 09:08 作者: 可卡 時(shí)間: 2025-3-30 16:23
Mechanism of Action of Direct-Acting Antivirals: New Insights into the HCV Life Cycleg antivirals (DAA) that target hepatitis C virus (HCV) replication. Combination therapies targeting multiple viral proteins can increase the genetic barrier to resistance, and all-oral, interferon-free regimens combining different classes of DAA are proving highly effective in treating chronic hepat作者: Meditative 時(shí)間: 2025-3-30 20:31
Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapynd to study the mode of action of different antiviral therapies. Standard biphasic models well describe the viral load decline in the first 2–4?weeks of therapy, however the hypothesis of a constant clearance rate of the infected cells during longer treatment periods provides unrealistic estimates o
